|
1
|
DiNardo CD, Erba HP, Freeman SD and Wei
AH: Acute myeloid leukaemia. Lancet. 401:2073–2086. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Juliusson G, Hagberg O, Lazarevic VL,
Ölander E, Antunovic P, Cammenga J, Wennström L, Möllgård L, Brune
M, Jädersten M, et al: Improved survival of men 50 to 75 years old
with acute myeloid leukemia over a 20-year period. Blood.
134:1558–1561. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Song Y, Jia Y, Zhang G, Wei S, Li Y, Hu Y,
Hao Q, Wang Z, Fang Q, Tian Z, et al: Machine leaning algorithm on
chemotherapeutic drug resistance related gene classifier in acute
myeloid leukemia. Blood. 136:28–29. 2020. View Article : Google Scholar
|
|
4
|
Ma YR, Zhao T, Ma L, Hu LJ, Duan WB, Jiang
H, Huang XJ and Jiang Q: Variables associated with hematological
remission and survival in patients with acute myeloid leukemia
after induction failure and relapse. Zhonghua Xue Ye Xue Za Zhi.
43:644–650. 2022.(In Chinese). PubMed/NCBI
|
|
5
|
Wysota M, Konopleva M and Mitchell S:
Novel therapeutic targets in acute myeloid leukemia (AML). Curr
Oncol Rep. 26:409–420. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bazinet A and Kantarjian HM: Moving toward
individualized target-based therapies in acute myeloid leukemia.
Ann Oncol. 34:141–151. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nepstad I, Hatfield KJ, Grønningsæter IS
and Reikvam H: The PI3K-Akt-mTOR signaling pathway in human acute
myeloid leukemia (AML) cells. Int J Mol Sci. 21:29072020.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Feng Y, Cu X and Xin M: PI3Kδ inhibitors
for the treatment of cancer: A patent review (2015-present). Expert
Opin Ther Pat. 29:925–941. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tang Y, Zheng Y, Hu X, Zhao H and Cui S:
Discovery of potent and selective PI3Kδ inhibitors for the
treatment of acute myeloid leukemia. J Med Chem. 67:6638–6657.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liang X, Li F, Chen C, Jiang Z, Wang A,
Liu X, Ge J, Hu Z, Yu K, Wang W, et al: Discovery of
(S)-2-amino-N-(5-(6-chloro-
5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-
yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective
phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. Eur J Med Chem.
156:831–846. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jiang B, Qi J, Song Y, Li Z, Tu M, Ping L,
Liu Z, Bao H, Xu Z and Qiu L: Phase 1 clinical trial of the PI3Kδ
inhibitor YY-20394 in patients with B-cell hematological
malignancies. J Hematol Oncol. 14:1302021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jin J, Cen H, Zhou K, Xu X, Li F, Wu T,
Yang H, Wang Z, Li Z, Huang W, et al: A Phase Ib study of
linperlisib in the treatment of patients with relapsed and/or
refractory peripheral T-cell lymphoma. Clin Cancer Res.
30:4593–4600. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang T, Sun X, Qiu L, Su H, Cao J, Li Z,
Song Y, Zhang L, Li D, Wu H, et al: The oral PI3Kδ inhibitor
linperlisib for the treatment of relapsed and/or refractory
follicular lymphoma: A phase II, Single-Arm, Open-label clinical
trial. Clin Cancer Res. 29:1440–1449. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu J, Lu AD, Zhang LP, Zuo YX and Jia YP:
Study of clinical outcome and prognosis in pediatric core binding
factor-acute myeloid leukemia. Zhonghua Xue Ye Xue Za Zhi.
40:52–57. 2019.(In Chinese). PubMed/NCBI
|
|
15
|
Wu D, Li M, Hong Y, Jin L, Liu Q, Sun C,
Li L, Han X, Deng S, Feng Y, et al: Integrated stress response
activation induced by usnic acid alleviates BCL-2 inhibitor ABT-199
resistance in acute myeloid leukemia. J Adv Res. 74:621–635. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu J, Chen Y, Yu L and Yang L: Mechanisms
of venetoclax resistance and solutions. Front Oncol.
12:10056592022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu H, Hussain Z, Xie Q, Yan X, Zeng C,
Zhou G and Cao S: Targeting PI3K/AKT/mTOR pathway to enhance the
anti-leukemia efficacy of venetoclax. Exp Cell Res. 417:1131922022.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang K, Huang Y, Duan Y, Guo B, Ke Q,
Liao C and Cen H: Anti-tumor effect of PI3K inhibitor Linperlisib
on diffuse large B-cell lymphoma in vitro. Chin J Oncol Prev Treat.
16:56–61. 2024.(In Chinese).
|
|
19
|
Alkhatabi HA, Zohny SF, Shait Mohammed MR,
Choudhry H, Rehan M, Ahmad A, Ahmed F and Khan MI:
Venetoclax-resistant MV4-11 leukemic cells activate PI3K/AKT
pathway for metabolic reprogramming and redox adaptation for
survival. Antioxidants (Basel). 11:4612022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ren WX, Guo H, Lin SY, Chen SY, Long YY,
Xu LY, Wu D, Cao YL, Qu J, Yang BL, et al: Targeting cytohesin-1
suppresses acute myeloid leukemia progression and overcomes
resistance to ABT-199. Acta Pharmacol Sin. 45:180–192. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yao MY, Wang YF, Zhao Y, Ling LJ, He Y,
Wen J, Zheng MY, Jiang HL and Xie CY: BCL-2 inhibitor synergizes
with PI3Kδ inhibitor and overcomes FLT3 inhibitor resistance in
acute myeloid leukaemia. Am J Cancer Res. 12:3829–3842.
2022.PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vela L, Gonzalo O, Naval J and Marzo I:
Direct interaction of Bax and Bak proteins with Bcl-2 homology
domain 3 (BH3)-only proteins in living cells revealed by
fluorescence complementation. J Biol Chem. 288:4935–4946. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao J, Wu S, Wang D, Edwards H, Thibodeau
J, Kim S, Stemmer P, Wang G, Jin J, Savasan S, et al: Panobinostat
sensitizes AraC-resistant AML cells to the combination of
azacitidine and venetoclax. Biochem Pharmacol. 228:1160652024.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang X, Zhang X, Li BS, Zhai X, Yang Z,
Ding LX, Wang H, Liang C, Zhu W, Ding J and Meng LH: Simultaneous
targeting of PI3Kδ and a PI3Kδ-dependent MEK1/2-Erk1/2 pathway for
therapy in pediatric B-cell acute lymphoblastic leukemia.
Oncotarget. 5:10732–10744. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xie C, He Y, Zhen M, Wang Y, Xu Y and Lou
L: Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits
potent antitumor efficacy against acute myeloid leukemia. Cancer
Sci. 108:1476–1484. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xiang Q, Dong S and Li XH: A Review of
phosphocreatine 3 kinase δ subtype (PI3Kδ) and its inhibitors in
malignancy. Med Sci Monit. 27:e9327722021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zou L, Qi Y, Tang L, Du Y, Xiang M, Chen
X, Ma J and Yang Z: Clinical review considerations of class I PI3K
inhibitors in hematolymphatic malignancies by Center for Drug
Evaluation. Chin J Cancer Res. 34:415–421. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen Y, Wu T, Yang C, Lu M, Chen Z, Deng
M, Jia Y, Yang Y, Liu X, Wang H, et al: A pyridinesulfonamide
derivative FD268 suppresses cell proliferation and induces
apoptosis via inhibiting PI3K pathway in acute myeloid leukemia.
PLoS One. 17:e02778932022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang C, Gong Y, Gao Y, Deng M, Liu X, Yang
Y, Ling Y, Jia Y and Zhou Y: Design, synthesis and in vitro
biological evaluation of 2-aminopyridine derivatives as novel PI3Kδ
inhibitors for hematological cancer. Bioorg Med Chem Lett.
82:1291522023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Song G, Valdez BC, Li Y, Liu Y, Champlin
RE and Andersson BS: Synergistic cytotoxicity of sorafenib with
busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3
internal tandem duplications-positive acute myeloid leukemia cells.
Biol Blood Marrow Transplant. 20:1687–1695. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Daver N, Schlenk RF, Russell NH and Levis
MJ: Targeting FLT3 mutations in AML: Review of current knowledge
and evidence. Leukemia. 33:299–312. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Konopleva M, Pollyea DA, Potluri J, Chyla
B, Hogdal L, Busman T, McKeegan E, Salem AH, Zhu M, Ricker JL, et
al: Efficacy and biological correlates of response in a phase II
study of venetoclax monotherapy in patients with acute myelogenous
leukemia. Cancer Discov. 6:1106–1117. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Darici S, Alkhaldi H, Horne G, Jørgensen
HG, Marmiroli S and Huang X: Targeting PI3K/Akt/mTOR in AML:
Rationale and clinical evidence. J Clin Med. 9:29342020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cui J and Placzek WJ: Post-Transcriptional
regulation of Anti-apoptotic BCL2 family members. Int J Mol Sci.
19:3082018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Leverson JD, Zhang H, Chen J, Tahir SK,
Phillips DC, Xue J, Nimmer P, Jin S, Smith M, Xiao Y, et al: Potent
and selective small-molecule MCL-1 inhibitors demonstrate on-target
cancer cell killing activity as single agents and in combination
with ABT-263 (navitoclax). Cell Death Dis. 6:e15902015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Piddock RE, Bowles KM and Rushworth SA:
The role of PI3K isoforms in regulating bone marrow
microenvironment signaling focusing on acute myeloid leukemia and
multiple myeloma. Cancers (Basel). 9:292017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Serra V, Scaltriti M, Prudkin L, Eichhorn
PJ, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M,
Rodriguez S, et al: PI3K inhibition results in enhanced HER
signaling and acquired ERK dependency in HER2-overexpressing breast
cancer. Oncogene. 30:2547–2557. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kiyoi H, Kawashima N and Ishikawa Y: FLT3
mutations in acute myeloid leukemia: Therapeutic paradigm beyond
inhibitor development. Cancer Sci. 111:312–322. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lu Y, Liu B, Liu Y, Yu X and Cheng G: Dual
effects of active ERK in cancer: A potential target for enhancing
radiosensitivity (Review). Oncol Lett. 20:993–1000. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ondrisova L and Mraz M: Genetic and
Non-Genetic mechanisms of resistance to BCR signaling inhibitors in
B cell malignancies. Front Oncol. 10:5915772020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wolf P, Schoeniger A and Edlich F:
Pro-apoptotic complexes of BAX and BAK on the outer mitochondrial
membrane. Biochim Biophys Acta Mol Cell Res. 1869:1193172022.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mustafa M, Ahmad R, Tantry IQ, Ahmad W,
Siddiqui S, Alam M, Abbas K, Moinuddi n, Hassan MI, Habib S and
Islam S: Apoptosis: A comprehensive overview of signaling pathways,
morphological changes, and physiological significance and
therapeutic implications. Cells. 13:18382024. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ohanian M, Rozovski U, Kanagal-Shamanna R,
Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO,
et al: MYC protein expression is an important prognostic factor in
acute myeloid leukemia. Leuk Lymphoma. 60:37–48. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gu K, May HA and Kang MH: Targeting
molecular signaling pathways and cytokine responses to modulate
c-MYC in acute myeloid leukemia. Front Biosci (Schol Ed).
16:152024. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Carter JL, Hege K, Yang J, Kalpage HA, Su
Y, Edwards H, Hüttemann M, Taub JW and Ge Y: Targeting multiple
signaling pathways: The new approach to acute myeloid leukemia
therapy. Signal Transduct Target Ther. 5:2882020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hege Hurrish K, Qiao X, Li X, Su Y, Carter
J, Ma J, Kalpage HA, Hüttemann M, Edwards H, Wang G, et al:
Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and
transcriptional reprogramming and decreased mitochondrial function
in acute myeloid leukemia. Biochem Pharmacol. 205:1152832022.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li X, Su Y, Hege K, Madlambayan G, Edwards
H, Knight T, Polin L, Kushner J, Dzinic SH, White K, et al: The
HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the
antileukemic activity of venetoclax in preclinical models of acute
myeloid leukemia. Haematologica. 106:1262–1277. 2021.PubMed/NCBI
|
|
49
|
Basit F, Andersson M and Hultquist A: The
Myc/Max/Mxd network is a target of mutated Flt3 signaling in
hematopoietic stem cells in Flt3-ITD-Induced myeloproliferative
disease. Stem Cells Int. 2018:32869492018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kotani N and Ito K: Translatability of in
vitro potency to clinical efficacious exposure: A retrospective
analysis of FDA-approved targeted small molecule oncology drugs.
Clin Transl Sci. 16:1359–1368. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Salem AH and Menon RM: Clinical
pharmacokinetics and pharmacodynamics of venetoclax, a selective
B-cell lymphoma-2 inhibitor. Clin Transl Sci. 17:e138072024.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kobayashi T, Sato H, Miura M, Fukushi Y,
Kuroki W, Ito F, Teshima K, Watanabe A, Fujishima N, Kobayashi I,
et al: Overexposure to venetoclax is associated with
prolonged-duration of neutropenia during venetoclax and azacitidine
therapy in Japanese patients with acute myeloid leukemia. Cancer
Chemother Pharmacol. 94:285–296. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kuusanmäki H, Kytölä S, Vänttinen I,
Ruokoranta T, Ranta A, Huuhtanen J, Suvela M, Parsons A, Holopainen
A, Partanen A, et al: Ex vivo venetoclax sensitivity testing
predicts treatment response in acute myeloid leukemia.
Haematologica. 108:1768–1781. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Graham GG and Scott KF: Limitations of
drug concentrations used in cell culture studies for understanding
clinical responses of NSAIDs. Inflammopharmacology. 29:1261–1278.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Abosalim HM, El-Moselhy TF, Sharafeldin N,
Giovannuzzi S, Begines P, Nafie MS, Fahmy SA, Diab MK, Babker A,
Supuran CT, et al: Innovative design and synthesis of dual-acting
hCA IX/CDK-2 inhibitors through hetero ring fused pyrimidine
utilization for cutting-edge anticancer therapy: Zein nanoparticles
for in vivo lung cancer treatment. Bioorg Chem. 166:1090572025.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Nabih NW, Hassan H, Preis E, Schaefer J,
Babker A, Abbas AM, Amin MU, Bakowsky U and Fahmy SA:
Antibody-functionalized lipid nanocarriers for RNA-based cancer
gene therapy: Advances and challenges in targeted delivery.
Nanoscale Adv. 7:5905–5931. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wafik Nabih N, Nafie MS, Babker A, Alameen
AAM and Fahmy SA: Next-generation lipid nanocarriers for
Parkinson's therapy: Nose-to-brain innovations and clinical
prospects. Nanoscale. 17:27826–27848. 2025. View Article : Google Scholar : PubMed/NCBI
|
